Nanoparticle-Based Drug Delivery Systems for Tumor Treatment: Advancing Solutions to Overcome Drug Resistance

The potential of nanoparticles (NPs) as a drug delivery mechanism (DDM) has prompted extensive study and use of nanotechnology in tumor cell (TC) treatment. Compared to conventional medications, NP-based DDM offers greater stability and biocompatibility, enhanced absorption and preservation, and focused accuracy, which are some of its unique advantages. This drug-carrying technology has reached a new level with the use and improvement of composite nanoparticles (NPs), which combine the unique characteristics of multiple NPs. Additionally, NP-based DDMs have demonstrated effectiveness in overcoming cancer-related drug resistance (DR). Improving medical translation must address limited dose capacity, stability limitations, and potential harmful effects. Researchers are exploring ways to enhance DDM, including the development of novel drug-encapsulating techniques and modifications to NP surfaces. Potentially huge gains in treatment efficacy may result from optimizing medication integration in such systems. One obstacle to medical translation is stability issues. Applying protective covers and improving formulations are two methods that researchers are exploring to extend the lifespan of NPs. Additionally, before progressing with clinical trials, efforts are being made to minimize the likelihood of negative side effects by carefully selecting compounds that are biologically compatible for NP synthesis and conducting comprehensive toxicity evaluations. Following that, we continue with the innovation of nanoparticle design and functionalization; these types of delivery systems are poised to play a key role in various areas of next-generation tumour therapies. Which provides various offers through robust pathways to overcoming drug resistance, accelerating clinical translation.